Zentek (ZEN) AI Stock Analysis

• Market Cap: C$96.79M
• Dividend Yield: N/A
• Average Volume (3M): 66.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: 2225.73%
• EPS Growth: 25.94%
• Country: CA
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 107,543,560
• 10 Day Avg. Volume: 86,681
• 30 Day Avg. Volume: 66,239
• PEG Ratio: 0.88
• Price to Book (P/B): 11.24
• Price to Sales (P/S): 190.02
• P/FCF Ratio: -26.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.84 ▼(-17.35% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held back by weak financial performance—limited revenue scale, negative margins, and continued cash burn—only partially offset by a low-leverage balance sheet. Technicals add pressure as the stock trades below key moving averages with a negative MACD, while valuation signals are inconclusive due to negative earnings and no dividend data.

Positive Factors

IP & advanced materials focus

Zentek's clear strategic focus on graphene and nanotech, plus stated R&D and IP development, provides durable product differentiation. Ownership of IP and multiple commercialization routes (manufacturing, licensing, partnerships) create optionality and long-term entry barriers across industrial and medical coatings markets.

Low financial leverage

A very low debt-to-equity ratio gives Zentek structural financial flexibility: it reduces default risk, lowers interest burdens, and preserves capacity to raise capital or pursue partnerships. Over 2-6 months this improves runway and strategic optionality to advance commercialization without heavy interest drag.

High revenue growth rate

A reported ~1,358% revenue growth rate indicates emerging commercial traction from a small base. Persisting high growth suggests product-market validation and scaling potential; sustainably growing top line helps justify continued R&D and partner investment if the company can preserve margins while expanding volumes.

Negative Factors

Very small revenue base

Sub-$1M TTM revenue leaves the business far from commercial scale, limiting economies of scale and making fixed costs a larger share of revenue. This structural weakness increases sensitivity to single customers or product delays and constrains the firm's ability to self-fund growth over the next several months.

Negative profitability and cash burn

Consistent negative operating and free cash flow implies continued reliance on external financing or dilutive capital raises to fund operations. Structurally, this limits strategic freedom, risks shareholder dilution, and creates runway pressure until meaningful positive cash generation is achieved.

Gross margin deterioration

A move to negative gross margins signals structural cost or pricing problems at the product level. Even with rising revenue, negative unit economics hinder the path to profitability and make scaling riskier, reducing appeal to manufacturing partners and increasing the capital required to reach break-even.

Zentek Business Overview & Revenue Model

Company Description

Zentek Ltd. (ZEN) is a Canadian technology company specializing in advanced materials and innovative solutions for various industries, including healthcare, energy, and environmental sectors. The company is focused on developing and commercializing its proprietary graphene-based technologies, which are designed to enhance the performance and efficiency of products in fields such as air filtration, antimicrobial coatings, and energy storage.

How the Company Makes Money

Zentek generates revenue primarily through the commercialization of its graphene-based products and technologies. The company has established key partnerships with industry players and research institutions to develop and market its innovative solutions. Revenue streams include sales of its air filtration systems, licensing agreements for its intellectual property, and collaborative research contracts. Additionally, Zentek benefits from government grants and funding aimed at supporting innovative technological advancements, which further contribute to its earnings.

Zentek Financial Statement Overview

Summary

Overall fundamentals are weak due to very small TTM revenue (~$0.94M), deeply negative profitability, and ongoing cash burn (negative operating and free cash flow). The main offset is a comparatively stronger balance sheet with modest leverage (low debt-to-equity), providing some financial flexibility despite persistent losses.

Income Statement

TTM (Trailing-Twelve-Months) revenue is still very small (~$0.94M) despite a positive growth rate, and profitability remains deeply negative. Gross margin in TTM turned negative (from positive in the latest annual period), and operating losses are large relative to revenue (EBIT and net margin both highly negative), indicating the business is not yet operating at commercial scale. The main positive is improving top-line trajectory versus prior years, but current economics and loss intensity keep the income statement profile weak.

Balance Sheet

The balance sheet is a relative strength: leverage is modest with low debt versus equity in both TTM and annual periods (debt-to-equity well below 0.2). Total assets are meaningful relative to the company’s revenue base, providing some financial flexibility. The key weakness is continued large losses driving very negative returns on equity, which can pressure equity over time if losses persist.

Cash Flow

Cash generation remains a clear concern: operating cash flow and free cash flow are consistently negative across periods, indicating ongoing cash burn to fund operations. While free cash flow has shown periods of improvement (including positive growth in TTM), the company is still not self-funding, and cash outflows remain sizable relative to the current revenue run-rate. A positive offset is that cash burn is broadly aligned with accounting losses (free cash flow roughly in line with net loss), but profitability/cash break-even is not yet in sight based on the data provided.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	942.88K	872.50K	29.82K	72.86K	339.67K	2.35K
Gross Profit	-705.11K	192.49K	-385.06K	-780.48K	-275.04K	-124.44K
EBITDA	-7.86M	-9.35M	-11.08M	-13.75M	-11.27M	-3.73M
Net Income	-8.08M	-10.04M	-11.70M	-14.41M	-38.69M	-3.87M
Balance Sheet
Total Assets	17.38M	18.40M	22.59M	33.29M	37.98M	30.25M
Cash, Cash Equivalents and Short-Term Investments	1.80M	121.48K	3.52M	10.36M	26.68M	3.09M
Total Debt	1.92M	680.47K	1.24M	1.61M	2.23M	404.32K
Total Liabilities	5.04M	3.65M	2.41M	2.90M	3.44M	2.79M
Stockholders Equity	12.34M	14.75M	20.17M	30.38M	34.55M	27.46M
Cash Flow
Free Cash Flow	-6.00M	-6.28M	-8.37M	-15.23M	-11.97M	-2.05M
Operating Cash Flow	-5.62M	-6.28M	-8.05M	-12.96M	-7.99M	-1.79M
Investing Cash Flow	1.75M	358.65K	1.88M	-2.31M	-7.25M	-1.23M
Financing Cash Flow	4.18M	2.52M	-665.47K	-1.05M	38.82M	5.31M

Zentek Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZEN, the sentiment is Neutral. The current price of 1.02 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.98, and below the 200-day MA of 1.24, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 72.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ZEN.

Zentek Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	68 Neutral	C$101.75M	211.50	0.87%	―	2.14%	-83.06%
QIPT	55 Neutral	C$220.99M	-36.01	-10.51%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	48 Neutral	C$65.16M	-32.47	―	―	-21.89%	26.36%
ZEN	46 Neutral	C$96.79M	-9.55	-52.95%	―	2225.73%	25.94%
ARCH	44 Neutral	C$52.88M	-54.08	―	―	―	10.49%
SONA	41 Neutral	C$40.68M	-21.43	-2846.90%	―	―	10.97%

Zentek Corporate Events

Zentek Taps Government Programs to Fast-Track Albany Graphite Development

Zentek has outlined a comprehensive government engagement strategy to accelerate development of its Albany Graphite Project toward a new Preliminary Economic Assessment and ultimately a Pre-Feasibility Study. Positioned as a potential domestic source of nuclear-grade, defence-critical graphite, the project aligns with NATO’s designation of graphite as essential and with Canada’s new Defence Industrial Strategy emphasizing secure mineral supply for allied defence.

The company is actively pursuing non-dilutive support from multiple federal programs tied to Canada’s Critical Minerals Strategy, including equity-style funds, R&D grants, and clean technology tax credits that could underpin its proprietary purification technology and future processing facilities. In Ontario, Zentek aims to leverage provincial critical minerals funds, streamlined permitting under the “One Project, One Process” framework, and the province’s strong nuclear power ecosystem, which together could accelerate project timelines and enhance Zentek’s strategic positioning in North American and allied critical mineral supply chains.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$0.75 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek Wins Nasdaq Extension to Meet Minimum Bid Price Rule

Zentek Ltd. has secured a 180-day extension from Nasdaq to regain compliance with the exchange’s minimum bid price requirement, giving the company until August 24, 2026, to lift its share price back above US$1.00 for at least ten consecutive trading days. Its Nasdaq listing and trading under the ticker ZTEK remain unaffected in the meantime, but management says it will closely monitor the stock and consider available options to restore compliance, a process that could influence capital-market access and investor confidence.

The extension relieves immediate delisting pressure but underscores ongoing market challenges for Zentek as it advances its graphene-enabled advanced material technologies across healthcare, clean air, and industrial markets. Maintaining Nasdaq status is strategically important for visibility and liquidity, particularly as the company seeks to commercialize its materials solutions and tap demand in high-value graphite applications for nuclear, battery, and semiconductor sectors.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$0.75 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek Sharpens Strategy Around High‑Purity Albany Graphite and Core Platforms

Zentek outlined a strategic reset centered on strict capital discipline, execution against clearly defined milestones, and a sharper focus on its three core platforms: the Albany Graphite project, ZenGUARD and Triera. The company has moved to cut costs, pause or wind down non‑core initiatives, and tie future financings to evidence‑based milestones to better align capital allocation with value creation.

Management highlighted Albany Graphite as its lead value‑creation asset amid rising North American demand for ultra‑high‑purity graphite in electric vehicles, nuclear energy, data centers and advanced electronics. Independent testing showing Albany material can be purified to 5N levels suitable for nuclear applications using a halogen‑free process reinforces its strategic importance and underpins plans to update the project’s economic assessment and expand pilot‑scale processing to de‑risk the asset and prepare for a pre‑feasibility study.

The most recent analyst rating on (TSE:ZEN) stock is a Sell with a C$0.81 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek Unveils Strategic Reset, Concentrates on Three Core Platforms

Zentek Ltd. has launched a strategic reset that narrows its focus to three core platforms—Albany Graphite, ZenGUARD and Triera—each governed by defined milestones, capital allocation criteria and a 24‑month roadmap, while pausing or winding down non-core initiatives to concentrate resources on projects with clearer paths to value creation. The company is cutting costs through workforce and facility optimization, tightening corporate spending and linking future capital raises to specific milestones, while redistributing the responsibilities of the departing Chief Science Officer across its existing technical leadership; management is also committing to improved transparency via clearer segment-level financial disclosure and milestone tracking, moves aimed at protecting and rebuilding shareholder value and sharpening execution for investors and other stakeholders.

The most recent analyst rating on (TSE:ZEN) stock is a Sell with a C$0.99 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek’s Albany Graphite Wins Nuclear‑Grade Validation, Targeting High‑Value Specialty Markets

Zentek’s Albany Graphite subsidiary has received final independent test results confirming that its ultra‑high‑purity Albany graphite, when used in near‑net‑shaped graphite bricks, meets key performance benchmarks for nuclear‑grade graphite blocks, including strength, density, electrical characteristics and extremely low impurity levels. This validation, building on prior confirmation of five‑nines purity and nuclear‑relevant boron thresholds, positions Albany’s purified natural graphite as a credible substitute for synthetic graphite in a range of high‑return, specialty applications, from advanced nuclear reactors to premium battery and high‑temperature components, potentially reducing reliance on foreign synthetic supply and enhancing Canada’s role in critical, security‑sensitive graphite markets as global demand for ultra‑high‑purity material grows.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$0.97 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek’s Albany Graphite Achieves Nuclear-Grade Performance, Targeting High-Value Specialty Markets

Zentek announced that independent testing has confirmed its Albany graphite achieves nuclear-grade performance in finished graphite bricks, meeting stringent benchmarks for strength, density, electrical performance and ultra-low impurity levels. With demonstrated five-nines purity and nuclear-spec suitability, management believes Albany graphite can substitute for synthetic graphite in high-value niches, positioning the project as a potential premier Canadian supplier of purified, ultra-high-purity natural graphite into nuclear, defense, aerospace, and premium battery markets, reducing reliance on foreign sources and aligning with growing demand and critical-mineral security objectives.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$0.97 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Zentek’s Albany Graphite Achieves Breakthrough Lithium-Ion Battery Performance

Zentek Ltd.’s subsidiary, Albany Graphite Corp., has achieved near-theoretical anode performance using its high-purity Albany graphite material in independent testing for lithium-ion batteries. The coin cell tests demonstrated exceptional energy storage capability and strong cycling stability, making the material a competitive option for high-performance battery applications. The efficient use of spheroidization byproducts and industry-standard testing further add to its economic value, sustainability appeal, and scalability, solidifying its potential in the North American battery supply chain. The breakthrough enhances Zentek’s position as a credible supplier of sustainable, high-performance graphite solutions, bolstering confidence among investors, partners, and battery manufacturers.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.